Bioretec Ltd Expands Share Capital
Bioretec Ltd has recently made significant strides in its growth journey by successfully registering a total of 60,000 new shares. This subscription has been executed under their option rights as part of the 2018-1A program. These developments reflect the company’s ongoing commitment to enhancing its market presence and accommodating its growing investor base.
Details on the Share Registration
The new shares have been registered with the trade register maintained by the Finnish Patent and Registration Office. This process marks an important milestone for Bioretec as they expand their total number of shares to 24,626,474. The total amount of subscription is recorded as EUR 90,000, ensuring the funds are allocated to Bioretec's reserve of invested unrestricted equity.
Impact on Shareholder Rights
Upon completion of the registration, the newly issued shares will confer shareholder rights to the investors effective immediately. These new shares are expected to be available in the book-entry system shortly, enhancing the trading options for existing and prospective shareholders. Trading of these shares is anticipated to begin on the Nasdaq First North Growth Market Finland soon.
About Bioretec and Its Innovations
Bioretec is at the forefront of medical technology, specializing in biodegradable orthopedic implants. With a focus on enhancing bone growth and expediting fracture healing, the company has pioneered a range of innovative products that are now utilized in about 40 countries worldwide.
The RemeOs™ Product Line
Among Bioretec’s groundbreaking innovations is the RemeOs™ product line, which showcases a new class of biodegradable materials forged from a magnesium alloy and hybrid composites. These implants are designed to be absorbed by the body, thus negating the need for removal surgeries. This unique feature not only promotes better surgical results but also aligns with the Value-Based Healthcare approach, which emphasizes patient benefits alongside clinical efficiency.
Market Authorization Achievements
In a significant step for the company, market authorization for the first RemeOs™ product has already been secured in the U.S. as of March 2023, followed by CE mark approval in Europe in January 2025. This positions Bioretec to capture a significant share of the global orthopedic trauma and spine market, which is estimated to exceed USD 9 billion.
Leadership and Contact Information
The company’s leadership remains focused on these ambitious growth targets. For any inquiries, individuals can reach out to Sarah van Hellenberg Hubar-Fisher, Interim CEO, or Johanna Salko, CFO, through their provided phone numbers. Furthermore, Nordic Certified Adviser AB serves as Bioretec's certified adviser, ensuring compliance and guiding the company's market activities.
Vision for the Future
With a clear vision for innovation and improvement in patient care, Bioretec is dedicated to its mission: Better healing means a better life. This principle drives them as they continue to develop and refine their product offerings in the ever-evolving medical landscape.
Frequently Asked Questions
What new shares has Bioretec Ltd registered?
Bioretec Ltd has registered 60,000 new shares subscribed through their option rights program, increasing their total shares to 24,626,474.
When did the share registration occur?
The new shares were registered on May 20, and trading is expected to commence shortly thereafter.
What is the significance of the RemeOs™ product line?
The RemeOs™ product line represents Bioretec's advancements in biodegradable orthopedic implants, aimed at improving surgical outcomes and patient care.
How does Bioretec ensure shareholder rights for new shares?
Shareholder rights for the new shares will be effective immediately upon registration, providing investors with ownership benefits.
Who can I contact for more information about Bioretec?
For inquiries, you can contact Sarah van Hellenberg Hubar-Fisher or Johanna Salko, who are both available through their respective contact numbers.
